UK Exports to US Plunge 25 Following Trumps Liberation Day Tariffs Trade Deficit Emerges
Analyst Coverage Initiated on Pinterest Inc as Market Evaluates Social Media Platforms Potential
One House Three Owners How the American Dream of Homeownership Grows More Costly
OpenAIs Potential IPO Valuation Trends and Key Risks to Watch
Dow Jones Futures Edge Higher as SP 500 and Nasdaq Reach New Peaks AI Stocks in Focus
JPMorgans Summer Reading List for the Affluent Highlights AI Leadership and Curious Lessons from Lemons
Beneficient BENF Q1 2026 Earnings Stellar EPS Surprise Amid Revenue Discretion Highlights Financial Resilience
Weyco Group Q1 2026 Earnings Steady EPS Performance Amid Challenging Retail Environment
FSBW Q1 2026 Earnings Modest EPS Beat Highlights Stability Amid Soft Stock Response
WAB Q1 2026 Earnings EPS Surpasses Estimates by Nearly 7 Stock Climbs
Oxford Industries OXM Q1 2026 Earnings Significant EPS Miss but Shares Rally
XOMA Royalty Corporation Q1 2026 Earnings EPS Misses Estimates Royalty Revenues Under Scrutiny
Aprea Therapeutics APRE Edges Higher Amid Light Trading Key Resistance at 099 in Focus
Oxford Square Capital Notes OXSQG Slides Slightly Amid FixedIncome Pressures
WD40 Company WDFC Posts Measured Gain as Shares Approach Key Resistance
Harvard Ave Acquisition Corp Rights HAVAR Gains on Low Volume Key Levels in Focus
Lexicon Pharmaceuticals LXRX Slides 31 as Shares Test Key Support Levels
Jamaica Weighs Oil Drilling Ambitions Against Green Commitments After Hydrocarbon Discovery
GRWG Q1 2026 Earnings Narrower Loss Surprises Estimates Shares Edge Higher
Argan Inc AGX Gains 383 Testing Resistance After Strong Momentum
RRX Q1 2026 Earnings EPS Surpasses Estimates by 152 Shares Dip 262
CTKB Q1 2026 Earnings EPS Misses Estimates as Operating Losses Widen
HIW Q1 2026 Earnings Massive EPS Surprise of 161 Drives Stock Rally
CRVO Q1 2026 Earnings EPS Miss Reflects Continued Clinical Investment
LMRI Q1 2026 Earnings EPS Surges Past Estimates Signaling Strong Operational Momentum
AVR Q1 2026 Earnings Wider Than Expected Losses as PreRevenue Biotech Advances
PRAX Q1 2026 Earnings EPS Beat Amid Continued RD Focus